Cargando…
Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
Sinomenine (SIN) is a benzyltetrahydroisoquinoline-type alkaloid isolated from the dried plant root and stem of Sinomenium acutum (Thumb.) Rehd.et Wils, which shows potent anti-inflammatory and analgesic effects. As a transforming disease-modifying anti-rheumatic drug, SIN has been used to treat rhe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781253/ https://www.ncbi.nlm.nih.gov/pubmed/36559313 http://dx.doi.org/10.3390/pharmaceutics14122820 |
_version_ | 1784857028708007936 |
---|---|
author | Chen, Xin Lu, Chengcheng Duan, Yanwen Huang, Yong |
author_facet | Chen, Xin Lu, Chengcheng Duan, Yanwen Huang, Yong |
author_sort | Chen, Xin |
collection | PubMed |
description | Sinomenine (SIN) is a benzyltetrahydroisoquinoline-type alkaloid isolated from the dried plant root and stem of Sinomenium acutum (Thumb.) Rehd.et Wils, which shows potent anti-inflammatory and analgesic effects. As a transforming disease-modifying anti-rheumatic drug, SIN has been used to treat rheumatoid arthritis over twenty-five years in China. In recent years, SIN is also in development for use against other disorders, including colitis, pain, traumatic brain injury, and uveitis. However, its commercial hydrochloride (SIN-HCl) shows low oral bioavailability and certain allergic reactions in patients, due to the release of histamine. Therefore, a large number of pharmaceutical strategies have been explored to address these liabilities, such as prolonging release behaviors, enhancing skin permeation and adsorption for transdermal delivery, targeted SIN delivery using new material or conjugates, and co-amorphous technology. This review discusses these different delivery strategies and approaches employed to overcome the limitations of SIN for its efficient delivery, in order to achieve improved bioavailability and reduced side effects. The potential advantages and limitations of SIN delivery strategies are elaborated along with discussions of potential future SIN drug development strategies. |
format | Online Article Text |
id | pubmed-9781253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97812532022-12-24 Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug Chen, Xin Lu, Chengcheng Duan, Yanwen Huang, Yong Pharmaceutics Review Sinomenine (SIN) is a benzyltetrahydroisoquinoline-type alkaloid isolated from the dried plant root and stem of Sinomenium acutum (Thumb.) Rehd.et Wils, which shows potent anti-inflammatory and analgesic effects. As a transforming disease-modifying anti-rheumatic drug, SIN has been used to treat rheumatoid arthritis over twenty-five years in China. In recent years, SIN is also in development for use against other disorders, including colitis, pain, traumatic brain injury, and uveitis. However, its commercial hydrochloride (SIN-HCl) shows low oral bioavailability and certain allergic reactions in patients, due to the release of histamine. Therefore, a large number of pharmaceutical strategies have been explored to address these liabilities, such as prolonging release behaviors, enhancing skin permeation and adsorption for transdermal delivery, targeted SIN delivery using new material or conjugates, and co-amorphous technology. This review discusses these different delivery strategies and approaches employed to overcome the limitations of SIN for its efficient delivery, in order to achieve improved bioavailability and reduced side effects. The potential advantages and limitations of SIN delivery strategies are elaborated along with discussions of potential future SIN drug development strategies. MDPI 2022-12-16 /pmc/articles/PMC9781253/ /pubmed/36559313 http://dx.doi.org/10.3390/pharmaceutics14122820 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chen, Xin Lu, Chengcheng Duan, Yanwen Huang, Yong Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug |
title | Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug |
title_full | Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug |
title_fullStr | Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug |
title_full_unstemmed | Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug |
title_short | Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug |
title_sort | recent advancements in drug delivery of sinomenine, a disease-modifying anti-rheumatic drug |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781253/ https://www.ncbi.nlm.nih.gov/pubmed/36559313 http://dx.doi.org/10.3390/pharmaceutics14122820 |
work_keys_str_mv | AT chenxin recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug AT luchengcheng recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug AT duanyanwen recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug AT huangyong recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug |